{"name":"Laboratoires Besins International","slug":"laboratoires-besins-international","ticker":"","exchange":"","domain":"","description":"Laboratoires Besins International is a specialty pharmaceutical company focused on the research, development, and commercialization of treatments for endocrine disorders, particularly in the area of testosterone replacement therapy. The company's lead product, Testogel, is a phase 3 drug used for testosterone replacement in men with hypogonadism.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Testogel 1%","genericName":"Testogel 1%","slug":"testogel-1","indication":"Treatment of hypogonadism in males","status":"phase_3"}]}],"pipeline":[{"name":"Testogel 1%","genericName":"Testogel 1%","slug":"testogel-1","phase":"phase_3","mechanism":"Testogel 1% is a topical testosterone gel used to treat hypogonadism in males.","indications":["Treatment of hypogonadism in males"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}